Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENZ215 biosimilar denosumab bioequivalence study in healthy volunteers
NCT05245669Phase 1Completed
- Sponsor
- Enzene Biosciences
- Start
- Jan 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of denosumab-nxxp in osteoporosis (3 arms), sponsored by Enzene Biosciences. Primary endpoints: Maximum Observed Drug Concentration at 270 days, Area Under the Drug Concentration-time Curve From Day 0 to Day 270 and 1 more. Started Jan 2022; status: completed.
02
Drugs
denosumab-nxxp
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05245669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245669.